AQR Capital Management
ADCT icon

AQR Capital Management’s ADC Therapeutics ADCT Stock Holding History

AQR Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$704K Buy
658,125
+420,488
+177% +$1.23M ﹤0.01% 3205
2026
Q1 		$891K Buy
237,637
+31,061
+15% +$122K ﹤0.01% 2831
2025
Q4 		$729K Buy
206,576
+61,324
+42% +$249K ﹤0.01% 2718
2025
Q3 		$581K Buy
145,252
+4,672
+3% +$14.7K ﹤0.01% 2734
2025
Q2 		$377K Sell
140,580
-60,590
-30% -$127K ﹤0.01% 2753
2025
Q1 		$284K Buy
201,170
+161,808
+411% +$275K ﹤0.01% 2715
2024
Q4 		$78.3K Buy
39,362
+17,255
+78% +$45.2K ﹤0.01% 2785
2024
Q3 		$69.6K Buy
+22,107
New +$69.7K ﹤0.01% 2686

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AQR Capital Management's ADCT Position: Q2 2026 in Review

AQR Capital Management increased its ADC Therapeutics (ADCT) stake by 177% in Q2 2026, buying an estimated $1.23M and bringing the position to 658,125 shares worth $704K. The position accounts for ﹤0.01% of the portfolio, ranked #3205.

AQR Capital Management first reported a position in ADCT in Q3 2024 and has held it in 8 quarters since. The position peaked at $891K in Q1 2026. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • AQR Capital Management held 658,125 shares of ADC Therapeutics worth $704K as of Q2 2026.
  • AQR Capital Management bought 420,488 ADC Therapeutics shares in Q2 2026, an estimated $1.23M.
  • ADC Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #3205 holding.
  • AQR Capital Management first reported a position in ADC Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • AQR Capital Management's ADC Therapeutics position peaked at $891K in Q1 2026.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.